Announcements Trials
Browse Landscape

Phase

Phase NA 49Phase 3 6Phase 4 5Phase 2 4Phase 1 4Phase 1/2 1

Status

Completed 4Unknown 3Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 1Other 1Lymphoid 1Genitourinary 1

Conditions

Neoplasms 1330Breast Neoplasms 686Carcinoma, Non-Small-Cell Lung 543Neoplasm Metastasis 436Lymphoma 435Leukemia, Myeloid, Acute 432Melanoma 402Prostatic Neoplasms 380Multiple Myeloma 364Lymphoma, Non-Hodgkin 355Ovarian Neoplasms 343Colorectal Neoplasms 333Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Pancreatic Neoplasms 328Leukemia, Lymphocytic, Chronic, B-Cell 323Leukemia 282Lung Neoplasms 275Glioblastoma 266Unspecified Adult Solid Tumor, Protocol Specific 257Recurrence 252Lymphoma, Follicular 248Lymphoma, Large B-Cell, Diffuse 245Brain Neoplasms 232Lymphoma, Mantle-Cell 210Carcinoma, Renal Cell 193Hodgkin Disease 192Head and Neck Neoplasms 192Myelodysplastic Syndromes 187Burkitt Lymphoma 172Glioma 171

Interventions

ficlatuzumab 1Metformin 1Fish Oils 1Erlotinib Hydrochloride 1Docosahexaenoic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Completed × Cardiovascular Diseases × Clear all
NCT04116203 2025-02-28

PCOS

University of Alberta

Phase 1 Completed
52 enrolled
Other

Cardiovascular Diseases, Diabetes Mellitus, Obesity, Polycystic Ovary Syndrome, Lipid Metabolism Disorders

NCT01043939 2014-12-31

JAVA

University of Minnesota

Phase 1 Completed
24 enrolled 20 charts

Cardiovascular Diseases

NCT00725634 2014-01-27

P05538

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
41 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasms, Plasma Cell

NCT00886353 2009-12-31

Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)

Apeiron Biologics

Phase 1 Completed
22 enrolled
Genitourinary

Cardiovascular Diseases, Kidney Diseases, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡